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Abstract: We examined the effects of L-ascorbic acid and its analogues on 
DNA synthesis and cell proliferation. We also investigated the signal 
transduction pathways involved in the induction of mitogenesis by 
L-ascorbic acid and its analogues using primary cultures of adult rat 
hepatocytes. Following a 4-h serum-free cultivation, both L-ascorbic acid 
and its stable analogue, L-ascorbic acid 2-glucoside, time- and 
dose-dependently stimulated hepatocyte DNA synthesis and cell 
proliferation, with EC50 values of 6.46  10-8 M and 3.34  10-8 M, 
respectively. Dehydroascorbic acid (10-6 M - 10-5 M) weakly stimulated 
hepatocyte mitogenesis, whereas isoascorbic acid (10-9 M – 10-5 M) had no 
effect. Hepatocyte mitogenesis induced by L-ascorbic acid or L-ascorbic acid 
2-glucoside was dose-dependently abolished by treatment with monoclonal 
antibodies against insulin-like growth factor (IGF)-I receptor, but not by 
treatment with monoclonal antibodies against insulin receptor or IGF-II 
receptor. Western blot analysis showed that both L-ascorbic acid and 
L-ascorbic acid 2-glucoside significantly stimulated IFG-I receptor tyrosine 
kinase activity within 3 min, and mitogen-activated protein (MAP) kinase 
activity within 5 min. These results demonstrate that both L-ascorbic acid 
and L-ascorbic acid 2-glucoside induce DNA synthesis and cell proliferation 
in primary cultures of adult rat hepatocytes by interacting with the IGF-I 
receptor site and by activating the receptor tyrosine kinase/MAP kinase 
pathway. 
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1. Introduction 
Mature rat liver in its normal state is quiescent. However, after extensive 
hepatic resection, the remaining hepatocytes proliferate to restore the 
original mass within 2 weeks (Michalopoulos and DeFrances, 1997; Fasto, 
2000). This regenerative process is regulated by multiple factors such as 
peptide growth factors, cytokines, and intermediary metabolites. For 
example, epidermal growth factor (EGF), hepatocyte growth factor (HGF), 
insulin-like growth factor (IGF), and transforming growth factor (TGF)- 
all stimulate DNA synthesis in hepatocytes in vivo and in vitro (Borowiak 
et al., 2004; Fasto et al., 2006). In the past decade, the cellular and 
molecular mechanisms of action of these multiple factors have been 
investigated in vitro using primary culture systems (Kimura and Ogihara, 
1997a,b, 1998, 2005; Kimura et al., 2009). In contrast, the role of vitamins 
in regulating hepatocyte mitogenesis remains to be elucidated. 
L-Ascorbic acid, also known as vitamin C, is a nutritional supplement 
essential for preventing scurvy. Human and non-human primates cannot 
synthesize L-ascorbic acid, and therefore, it must be provided exogenously 
and transported intracellularly, a process that is mediated by transporters 
located at the cell membrane (Vera et al., 1994; Savini et al., 2008). 
L-Ascorbic acid is classified as a water-soluble vitamin, as are vitamins B6 
and B12. L-Ascorbic acid is reversibly oxidized in the body to 
dehydroascorbic acid, which retains full vitamin C activity. Vitamin C is an 
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essential nutrient for the biosynthesis of collagen and L-carnitine, and for 
the conversion of dopamine to norepinephrine (Tajima and Pinnel, 1982; Li 
and Schellhorn, 2007). The liver is an important target for the antioxidant 
effects of vitamin C, and plays a role in body vitamin homeostasis. Several 
reviews have summarized our current understanding of the physiology and 
pharmacology of vitamin C (Arrigoni and Tullio, 2002; Konya and 
Ferdinandy, 2006; Mandl et al., 2009). 
L-ascorbic acid and its derivatives can inhibit or stimulate the growth of 
normal and tumor cells, depending on the cell type (Alcain and Burton, 
1994; Belin et al., 2009; Koh et al., 1998; Pelin et al., 2009; Yang et al., 
2006; Shibayama et al., 2008). However, the cellular mechanisms of this 
inhibition or stimulation are poorly understood. Using primary cultures of 
adult rat hepatocytes, our aim was to test whether or not L-ascorbic acid 
and its analogues can stimulate hepatocyte DNA synthesis and cell 
proliferation, and if so, to analyze the signal transduction pathways 
involved. 
 
  5  
2. Materials and Methods 
2.1. Animals 
 Male Wistar rats (weight 200 – 220 g) were obtained from Saitama 
Experimental Animal Co. (Saitama, Japan). They were maintained in an 
alternating 12-h light/dark cycle, with food and water available ad libitum. 
The experimental protocol and handling of the animals during experiments 
were approved by the Experimental Animal Research Committee at the 
Josai University of Pharmaceutical Science, Japan. 
 
2.2. Hepatocyte isolation and culture 
The methods of hepatocyte isolation and culture have been described 
elsewhere (Nakamura et al., 1983). In brief, the rats were anesthetized 
with an intraperitoneal injection of sodium pentobarbital (45 mg/kg). 
Two-step in situ collagenase perfusion was performed to facilitate 
disaggregation of the adult rat liver, as described previously (Seglen, 1975). 
The viability of hepatocytes consistently exceeded 96%, as determined by 
the trypan blue exclusion assay. Unless otherwise indicated, isolated 
hepatocytes were plated onto 6-well collagen-coated plastic culture dishes 
(35 mm diameter; Iwaki Glass Co., Tokyo, Japan) at a density of 3.3  104 
cells/cm2 in minimum essential medium containing 5% bovine calf serum 
and 10-10 M dexamethasone for 3 h in 5% CO2 in air (Kimura et al., 2011). 
The medium was then changed, and the cells were cultured in serum-free 
  6  
minimum essential medium containing various concentrations of L-ascorbic 
acid or its analogues with or without specific inhibitors of signal 
transducers. In some experiments, the hepatocytes were cultured in 
serum-free minimum essential medium containing various concentrations 
of L-ascorbic acid or its analogues with or without monoclonal antibodies 
against several growth factor receptors and growth factors. In this study, 
minimum essential medium was used in place of Williams’ medium E 
because it does not contain L-ascorbic acid, vitamin E, or vitamin K. 
L-ascorbic acid, dehydroascorbic acid, isoascorbic acid and L-ascorbic acid 
2-glucoside were buffered at pH 7.0 with sodium hydroxide and prepared 
fresh before each experiment. 
 
2.3. Measurement of DNA synthesis 
Hepatocyte DNA synthesis was assessed by measuring [3H]-thymidine 
incorporation into acid-precipitable materials (Morley and Kingdon, 1972). 
After an initial attachment period of 3 h, the hepatocytes were washed 
twice with serum-free minimum essential medium and cultured in medium 
containing L-ascorbic acid or its analogues for a further 4 h or 21 h. The 
cells were pulse-stimulated for 2 h with [3H]-thymidine (1.0 Ci/well) at 2 h 
and 19 h following the addition of L-ascorbic acid or its analogues. 
Incorporation of [3H]-thymidine into DNA was determined as described 
previously (Kimura and Ogihara, 1997a). The hepatocyte protein content 
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was determined using a modified Lowry procedure (Lee and Paxman, 1972) 
using bovine serum albumin as the standard. Data are expressed as 
dpm/h/mg cellular protein. 
 
2.4. Counting the number of nuclei 
 The number of nuclei rather than the number of cells was counted, as 
previously described but with minor modifications (Nakamura et al., 1983). 
Briefly, the primary cultured hepatocytes were washed twice with 2 ml of 
Dulbecco’s phosphate-buffered saline (pH 7.4). Then, the cells were lysed by 
incubation in 0.25 ml of 0.1 M citric acid containing 0.1 % Triton X-100 for 
30 min at 37C. An equal volume of the nucleus suspension was mixed with 
0.3% trypan blue in Dulbecco’s phosphate-buffered saline (pH 7.4), and the 
nuclei were counted in a hemocytometer. 
 
2.5. Determination of IGF-I receptor tyrosine kinase activity 
 Tyrosine phosphorylation of the IGF-I receptor was identified by Western 
blotting using anti-phosphotyrosine antibody (Li et al., 1994). The 
phospho-IGF-I receptor antibody detects IGF-I receptor only when tyrosine 
1161 in the carboxyl-terminal region is phosphorylated. This antibody does 
not cross-react with other tyrosine phosphorylated proteins. In brief, 
hepatocytes were freshly isolated and seeded at a density of 3.3  104 
cells/cm2 and cultured in minimal essential medium containing 5% 
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newborn bovine serum. The medium was then aspirated and replaced, and 
the cells were further cultured in serum-free minimal essential medium 
with or without L-ascorbic acid or L-ascorbic acid 2-glucoside for various 
lengths of time. Cultured hepatocytes were washed once with ice-cold 
phosphate-buffered saline (pH 7.4) and then 0.2 ml of lysis buffer (20 mM 
Tris buffer, pH 7.5, 1% Triton X-100, 150 mM NaCl, 1 mM EDTA, 1 mM 
EGTA, 2.5 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 1 mM 
-glycerophosphate, 1 mM phenylmethylsulfonyl fluoride) was added. Cell 
lysates were obtained by scraping the cells in lysis buffer, followed by 
sonication for 3 min. Cell lysates were centrifuged (3000  g for 3 min at 
4C) to remove cellular debris, then denatured in boiling water for 5 min. 
For immunoblotting analysis, samples of the supernatant (30 g/lane) were 
resolved by sodium dodecyl sulfate (SDS)-polyacrylamide gel 
electrophoresis (PAGE) using a 7.5% polyacrylamide resolving gel, 
transferred to a polyvinylidene difluoride (PVDF) membrane, and 
immunoblotted with anti-phosphotyrosine antibody (Li et al., 1994). Blots 
were developed by enhanced chemiluminescence following incubation with 
horseradish peroxidase (HRP)-conjugated secondary antibodies. The 
tyrosine kinase activity (autophosphorylation) of the phosphorylated 
p95-kDa protein (P-p95-kDa) was normalized to that of the total p95-kDa 
protein. 
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2.6. Determination of MAP kinase activity 
Phosphorylated MAP kinase isoforms (P-p42 and P-p44 MAPK) were 
identified by Western blot analysis using a 1:1000 dilution of rabbit 
polyclonal dual phospho-specific antibodies (1 mg/ml) with HRP-conjugated 
goat anti-rabbit immunoglobulin G (IgG) as a secondary antibody, as 
previously described (Towbin et al., 1979; Okamoto et al., 2009). 
Phosphorylated MAP kinase activity was normalized to the total MAP 
kinase activity. The data were calculated in arbitrary units and are 
expressed as means ± standard error of the means (S.E.M.). Statistical 
significance was set at *P < 0.05 compared with medium alone. The 
autodiagram is a representation of three experiments using different cell 
preparations. 
 
2.7. Neutralization of growth factor receptors and growth factors 
In experiments employing neutralizing antibodies, serum-free primary 
cultured hepatocytes were treated with maximum concentrations of 
monoclonal antibodies against HGF receptor, EGF receptor, insulin 
receptor, IGF-I receptor, IGF-II receptor, and tumor necrosis factor (TNF)- 
receptor-1 in the presence of L-ascorbic acid or L-ascorbic acid 2-glucoside. 
In some experiments, serum-free primary cultured hepatocytes were 
treated with various concentrations of monoclonal antibodies against IGF-I 
receptors, IGF-I, and TGF- in the presence of L-ascorbic acid or L-ascorbic 
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acid 2-glucoside. 
 
2.8. Assay of [125I]-IGF-I binding 
 Hepatocytes were isolated and cultured as described in Section 2.2. After 
3h of culture, hepatocytes were washed 3 times with Hanks-10mM Hepes 
buffer (pH 7.4) supplemented with 8 mM glucose and 10 mg/mL bovine 
serum albumin. [125I]-IGF-I binding to primary cultures of hepatocytes was 
measured according to the method as described elsewhere (Caro et al., 
1988). Briefly, the hepatocytes were incubated at 20C for 2h with 
increasing concentrations of [125I]-IGF-I (1~150 pM) in the presence or 
absence of unlabeled IGF-I. Free [125I]-IGF-I was separated from bound by 
washing twice with fresh incubation buffer at 4C. The cells were 
solubilized in 0.5 mL of 0.2 M NaOH and radioactivity was counted by a 
gamma counter (Aloka 7001, Japan). Nonspecific binding was determined 
by incubation in the presence of 100 nM unlabeled IGF-I. Specific binding 
was calculated by subtracting nonspecific binding from total binding. 
Under the conditions employed, specific binding of [125I]-IGF-I to primary 
cultured hepatocytes was 80% of the total radioactivity bound. 
 
2.9. Competitive [125I]-IGF-I binding assay 
 The binding affinity of L-ascorbic acid and its analogues  
to IGF-I receptors was determined by competitive [125I]-IGF-I binding 
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studies. Briefly, the hepatocytes were incubated at 20C for 2h with 
[125I]-IGF-I (50 pM) in the presence or absence of increasing concentrations 
of unlabeled IGF-I or L-ascorbic acid and its analogues. Other experimental 
conditions were the same as described in Section 2.8. 
 
2.10. Materials 
 The following reagents were obtained from Sigma-Aldrich (St. Louis, MO, 
USA): AG1478 (N-[3-chlorophenyl]-6,7-dimethoxy-4-quinazolinamine), 
AG538 (-cyano-(3-methoxy-4-hydroxy-5-iodocinnamoyl)-(3’, 
4’-dihydroxyphenyl) ketone), D-(-)-isoascorbic acid, and dexamethasone. 
Rapamycin and PD98059 were obtained from R & D Systems (Minneapolis, 
MN, USA). Minimum essential medium and newborn calf serum were 
purchased from Flow Laboratories (Irvine, Scotland). Collagenase (type II) 
was obtained from Worthington Biochemical Co., (Freehold, NJ, USA). 
L-ascorbic acid, L-ascorbic acid 2-glucoside, and dehydroascorbic acid were 
obtained from Wako Pure Chemicals Co. (Osaka, Japan). Monoclonal 
antibodies against IGF-I and IGF-I receptor (Cat.No.GR11) were obtained 
from Oncogene Research Products (Cambridge, MA, USA). Polyclonal 
anti-IGF-I receptor (phospho-Tyr1161) antibody was obtained from Applied 
Biochemical Materials Inc. (Richmond, BC, Canada). Monoclonal 
antibodies against TNF receptor-1 and TGF- were obtained from Santa 
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Other antibodies were 
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obtained as follows: monoclonal antibody against HGF receptor (c-Met) 
(Cell Signaling Technology, Beverly, MA, USA), monoclonal antibody 
against EGF receptor (New England Biolabs, Beverly, MA, USA), 
monoclonal antibody against insulin receptor (-subunit) (Novus 
Biologicals, LLC, Littleton, CO, USA), and monoclonal antibody against 
IGF-II receptor (Epitomics, Inc., Burlingame, CA, USA). [Methyl 
3H]-thymidine (20 Ci/mmol) and [125I]-IGF-I (2705 Ci/mmol) were 
purchased from PerkinElmer life sciences (Boston, MA, USA). All other 
reagents were of analytical grade. 
 
2.9. Statistical analysis 
 Data are expressed as mean ± S.E.M. Group comparisons were made by 
analysis of variance (ANOVA) for unpaired data followed by post hoc 
analysis using Dunnett’s multiple comparison test. P values less than 0.05 
were regarded as statistically significant. 
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3. Results 
3.1. Time course of induced stimulation of hepatocyte DNA synthesis and 
cell proliferation induced by L-ascorbic acid and its analogues 
We examined the effects of L-ascorbic acid (vitamin C) and its analogues 
on DNA synthesis and nuclei number (cell proliferation) in primary 
cultures of adult rat hepatocytes. Cells were cultured in medium, with or 
without L-ascorbic acid or its analogues, for 4 h and 21 h. As shown in 
Figure 1, exogenous L-ascorbic acid (3  10-6 M) or L-ascorbic acid 
2-glucoside (10-6 M) induced hepatocyte DNA synthesis and cell 
proliferation. A significant increase in hepatocyte DNA synthesis occurred 
after 2.5 h of culture with L-ascorbic acid or L-ascorbic acid 2-glucoside. A 
significant increase in the number of nuclei (cell proliferation) was 
observed after 3.0 h of culture with L-ascorbic acid 2-glucoside, and after 
3.5 h of culture with L-ascorbic acid; in both cases, proliferation peaked at 4 
h and was sustained for a further 17 h. Dehydroascorbic acid (3  10-6 M) 
only weakly stimulated hepatocyte DNA synthesis and cell proliferation, 
and isoascorbic acid (3  10-6 M), a stereoisomer of L-ascorbic acid, had no 
effect. 
 
3.2. Dose-dependent effects of L-ascorbic acid and its analogues on 
hepatocyte DNA synthesis and cell proliferation 
 We next examined the dose-dependent effects of L-ascorbic acid and its 
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analogues on hepatocyte DNA synthesis and cell proliferation. Hepatocytes 
were treated with various concentrations of L-ascorbic acid or its analogues 
for 4 h in serum-free culture, then DNA synthesis and cell proliferation 
were measured. As shown in Figure 2, both L-ascorbic acid (10-9 – 10-5 M) 
and its stable analogue, L-ascorbic acid 2-glucoside (10-9 – 10-5 M), 
dose-dependently stimulated hepatocyte DNA synthesis and cell 
proliferation within 4 h of culture in serum-free medium. A maximum 
increase in DNA synthesis was observed with 3  10-6 M L-ascorbic acid 
and with10-6 M L-ascorbic acid 2-glucoside. The 50% effective concentration 
(EC50) occurred at 6.46  10-8 M L-ascorbic acid and 3.34  10-8 M L-ascorbic 
acid 2-glucoside, indicating that L-ascorbic acid 2-glucoside is more potent 
than L-ascorbic acid in stimulating hepatocyte DNA synthesis and cell 
proliferation. Dehydroascorbic acid (10-6 - 10-5 M) only weakly stimulated 
hepatocyte DNA synthesis and cell proliferation, and isoascorbic acid (10-9 
– 10-5 M), a stereoisomer of L-ascorbic acid, had no effect. Other lipid- 
soluble vitamins such as (+)--tocopherol (vitamin E; 10-9 – 10-5 M) and 
phylloquinone (vitamin K1; 10-9 – 10-5 M) also had no significant effect 
(data not shown). 
 
3.3. Effects of specific inhibitors of growth-related signal transducers on 
hepatocyte DNA synthesis and cell proliferation induced by L-ascorbic acid 
and L-ascorbic acid 2-glucoside 
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  We investigated whether or not the mitogenic responses of hepatocytes to 
L-ascorbic acid and L-ascorbic acid 2-glucoside were mediated by signal 
transducers, such as receptor tyrosine kinase, phosphatidylinositol 
3-kinase (PI(3)K), mitogen-activated protein (MAP) kinase, and ribosomal 
protein p70 S6 kinase, by using the corresponding specific inhibitors of the 
signal transducers. The inhibitors used were AG1478 (3  10-6 M), a specific 
inhibitor of receptor tyrosine kinase (Levizki and Gazit, 1995), LY294002 
(10-7 M), a specific inhibitor of PI(3)K  (Vlahos et al., 1994), PD98059 (10-6 
M), a specific inhibitor of MAP kinase kinase (Alessei et al., 1995), and 
rapamycin (10 ng/ml), a specific inhibitor of mammalian target of 
rapamycin (m-TOR; Chung et al., 1992; Price et al., 1992). These inhibitors 
alone had no significant effect on hepatocyte DNA synthesis and cell 
proliferation. However, when combined, AG1478 (3  10-6 M) and 
LY294002 (10-7 M) essentially blocked L-ascorbic acid (3  10-6 M)-induced 
or L-ascorbic acid 2-glucoside (10-6 M)-induced hepatocyte DNA synthesis 
and cell proliferation during 4 h of culture. PD98059 (10-6 M) attenuated 
L-ascorbic acid- or L-ascorbic acid 2-glucoside-induced hepatocyte DNA 
synthesis and cell proliferation, whereas, rapamycin (10 ng/ml) blocked the 
effects induced by L-ascorbic acid (3  10-6 M) or L-ascorbic acid 2-glucoside 
(10-6 M). 
 
 
  16  
3.4. Effect of anti-growth factor receptor monoclonal antibodies on 
hepatocyte DNA synthesis and cell proliferation induced by L-ascorbic acid 
and L-ascorbic acid 2-glucoside 
 Several intracellular signal-transducing elements are involved in 
L-ascorbic acid- and L-ascorbic acid 2-glucoside-induced hepatocyte DNA 
synthesis and cell proliferation, as shown in Figure 3. However, the 
receptors or binding sites that functionally interact with L-ascorbic acid 
and L-ascorbic acid 2-glucoside are unknown. To investigate which 
receptors may interact with the L-ascorbic acid signal transduction 
pathways, we tested monoclonal antibodies against known growth factor 
receptors and cytokine receptors to see whether or not they affect L-ascorbic 
acid- or L-ascorbic acid 2-glucoside-induced hepatocyte DNA synthesis and 
cell proliferation after 4 h of culture. As shown in Figure 4, hepatocyte 
DNA synthesis and cell proliferation induced by L-ascorbic acid (3  10-6 M) 
or L-ascorbic acid 2-glucoside (10-6 M) were radically inhibited by 
monoclonal anti-IGF-I receptor antibody (100 ng/ml). In contrast, 
L-ascorbic acid- and L-ascorbic acid 2-glucoside-induced hepatocyte DNA 
synthesis and cell proliferation were not significantly inhibited by 
monoclonal antibodies against IGF-II receptor (100 ng/ml), insulin receptor 
(100 ng/ml), EGF receptor (100 ng/ml), HGF receptor (100 ng/ml), or TNF- 
receptor-1 (100 ng/ml). These results indicate that anti-IGF-I receptor 
antibody specifically inhibits the effects of L-ascorbic acid (3  10-6 M) and 
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L-ascorbic acid 2-glucoside (10-6 M) on hepatocyte mitogenesis. 
 
3.5. Dose-dependent effects of monoclonal antibodies against IGF-I receptor, 
TGF-, and IGF-I on hepatocyte DNA synthesis and cell proliferation 
induced by L-ascorbic acid and L-ascorbic acid 2-glucoside 
 We next examined the dose-response relationship between monoclonal 
antibody against IGF-I receptor and hepatocyte mitogenesis. As shown in 
Figure 5, L-ascorbic acid- and L-ascorbic acid 2-glucoside-induced 
hepatocyte DNA synthesis and cell proliferation were dose-dependently 
inhibited by monoclonal antibody against IGF-I receptor antibody. The IC50 
values for these synthesis and proliferation effects after 4 h of culture were 
25 ng/ml and 35 ng/ml, respectively. In addition, to exclude the possibility 
that the autocrine factors, TGF- and IGF-I, mediate L-ascorbic acid- and 
L-ascorbic acid 2-glucoside-induced hepatocyte DNA synthesis and cell 
proliferation in primary cultures, we examined the effects of neutralizing 
monoclonal antibodies against TGF- and IGF-I. Figures 5A and 5B show 
that the addition of a neutralizing monoclonal antibody against IGF-I (1 – 
100 ng/ml) and TGF- (1 – 100 ng/ml) to cultures did not affect the 
growth-promoting effects of L-ascorbic acid and L-ascorbic acid 2-glucoside 
on hepatocyte DNA synthesis and cell proliferation. These monoclonal 
antibodies by themselves had no significant effect during 4 h of culture 
(data not shown). 
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3.6. Effects of L-ascorbic acid and L-ascorbic acid 2-glucoside on receptor 
tyrosine kinase and mitogen-activated protein (MAP) kinase activity in 
primary cultured hepatocytes 
To confirm that L-ascorbic acid and L-ascorbic acid 2-glucoside induce 
hepatocyte DNA synthesis and cell proliferation through the IGF-I receptor 
tyrosine kinase/MAP kinase signaling pathway, we investigated whether or 
not they stimulate receptor tyrosine kinase and MAP kinase activity. 
Figure 6A shows that both L-ascorbic acid and L-ascorbic acid 2-glucoside 
(10-6 M) stimulation increases the phosphorylation of IGF-I receptor 
tyrosine kinase, with phosphorylation peaking at about 3-fold (compared 
with the control) 3 min after the addition. The addition of AG1478 (3  10-6 
M) significantly inhibited the L-ascorbic acid- and L-ascorbic acid 
2-glucoside-induced increase in IGF-I receptor tyrosine kinase activity, 
whereas the addition of the more specific inhibitor, AG538 (10-7 M), 
completely abolished the increase. Figure 6B shows that L-ascorbic acid (3 
 10-6 M) and L-ascorbic acid 2-glucoside (10-6 M) stimulation caused an 
increase in the phosphorylation of p42 MAP kinase, peaking at about 3-fold 
(compared with the control) 5 min after the addition. The addition of 
PD98059 (10-6 M) completely abolished the L-ascorbic acid- and L-ascorbic 
acid 2-glucoside-induced increase in p42 MAP kinase activity. AG1478, 
AG538, and LY294002 inhibited the L-ascorbic acid- and L-ascorbic acid 
2-glucoside-induced increase in the phosphorylation of p42 MAP kinase 
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(Fig. 6B), whereas rapamycin had no effect (Fig. 6B). 
 
3.7. Effects of L-ascorbic acid and its analogues on [125I]-IGF-I binding to 
IGF-I receptors of primary cultured hepatocytes. 
We first characterized [125I]-IGF-I binding to IGF-I receptors of primary 
cultured hepatocytes according to the method described elsewhere (Caro et 
al., 1988). Specific binding of [125I]-IGF-I to IGF-I receptors was almost 
saturated at a concentration of 75 pM (Fig. 7A) and Scatchard analysis of 
its curve showed that the Kd value was 0.35 nM and the receptor density 
(Bmax) was 52.4 fmol/3.3x105 cells.  
Fig. 7B shows the competitive binding studies of [125I]-IGF-I in primary 
cultured hepatocytes. This figure demonstrates the specificity of L-ascorbic 
acid and L-ascorbic acid 2-glucoside to IGF-I receptors, as increasing 
concentrations of L-ascorbic acid and L-ascorbic acid 2-glucoside compete in 
a dose-dependent manner with [125I]-IGF-I from the binding sites. The IC50 
values for L-ascorbic acid and L-ascorbic acid 2-glucoside were 1.8x10-7 M 
and 5.4x10-8 M, respectively. Isoascorbic acid and dehydroascorbic acid 
have very low replacement activity. 
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4. Discussion 
 As shown in Figures 1 and 2, both L-ascorbic acid and its stable analogue, 
L-ascorbic acid 2-glucoside, time- and dose-dependently stimulate DNA 
synthesis and cell proliferation in primary cultures of adult rat hepatocytes. 
Isoascorbic acid, which has antioxidant activity but not the biological 
activity of vitamin C, did not affect hepatocyte mitogenesis, nor did other 
lipid-soluble vitamins such as vitamin E ((+) -tocopherol; 10-8 – 10-5 M), 
which has antioxidant properties, or vitamin K1 (phylloquinone; 10-8 – 10-5 
M) (data not shown). These results suggest that the stimulatory effects of 
L-ascorbic acid and L-ascorbic acid 2-glucoside on hepatocyte DNA 
synthesis and cell proliferation are unrelated to their antioxidant or 
hydrophilic properties. 
In order to clarify how L-ascorbic acid and L-ascorbic acid 2-glucoside 
induce hepatocyte DNA synthesis and cell proliferation, we investigated 
the effects of specific inhibitors of signal transducers on these responses in 
primary cultures of adult rat hepatocytes. Specific inhibitors of the 
intracellular signaling pathway are useful probes with which to 
characterize target proteins involved in the activation of hepatocyte DNA 
synthesis and cell proliferation induced by growth factors or cytokines in 
cultured adult rat hepatocytes (Kimura and Ogihara, 1997a,b; Okamoto et 
al., 2009). In the present study, hepatocyte DNA synthesis and cell 
proliferation induced by L-ascorbic acid and L-ascorbic acid 2-glucoside 
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were effectively blocked by AG1478, LY294002, PD98059, and rapamycin, 
suggesting that hepatocyte mitogenesis induced by L-ascorbic acid and 
L-ascorbic acid 2-glucoside is mediated, at least partially, through receptor 
tyrosine kinase, PI(3)K, MAP kinase kinase, and m-TOR (p70 S6K) (Figs. 3 
and 4). Although L-ascorbic acid and L-ascorbic acid 2-glucoside are 
believed to stimulate hepatocyte DNA synthesis and cell proliferation 
through these signal-transducing elements, their target sites remain 
unknown. 
We hypothesized that L-ascorbic acid and L-ascorbic acid 2-glucoside 
stimulate hepatocyte DNA synthesis and cell proliferation through known 
receptors that have functionally active binding sites for these two 
compounds. To investigate which receptors functionally produce L-ascorbic 
acid signaling pathways, we used specific monoclonal antibodies against 
growth-promoting receptors and investigated their ability to inhibit 
L-ascorbic acid- and L-ascorbic acid 2-glucoside-induced hepatocyte DNA 
synthesis and cell proliferation following 4 h of culture. As shown in 
Figures 4 and 5, L-ascorbic acid- and L-ascorbic acid 2-glucoside-induced 
hepatocyte mitogenesis was completely inhibited by monoclonal antibodies 
against IGF-I receptor, but not by antibodies against IGF-II receptor. In 
addition, monoclonal antibodies against insulin, EGF, HGF, and TNF-1 
receptor were also ineffective. 
To exclude the possibility that L-ascorbic acid and L-ascorbic acid 
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2-glucoside selectively stimulate the secretion of a primary mitogen in an 
autocrine manner, thus inducing hepatocyte mitogenesis, we examined the 
effects of neutralizing antibodies against autocrine factors. Mitogens that 
could fulfill this requirement are TGF- and IGF-I, since hepatocytes 
express mRNA for TGF- and IGF-I, and cells can synthesize and store 
these primary mitogens (Michalopoulos and DeFrances, 1997). Both TGF- 
and IGF-I are highly active growth factors for stimulating hepatocyte DNA 
synthesis and cell proliferation (Andus et al., 1991; Diehl and Rai, 1996; 
Fausto, 2000; Kimura and Ogihara, 1998; Kimura and Ogihara, 1999). As 
shown in Figures 5A and 5B, the addition of neutralizing monoclonal 
antibodies against IGF-I and TGF- to the culture medium did not affect 
the growth-promoting effect of L-ascorbic acid or L-ascorbic acid 2-glucoside 
on primary cultured hepatocytes, thereby suggesting that the autocrine 
hypothesis is not valid. Taken together, these results indicate that 
L-ascorbic acid and L-ascorbic acid 2-glucoside induce DNA synthesis and 
cell proliferation in adult rat hepatocytes by interacting with the IGF-I 
receptor. In agreement with these results (Figs. 3 and 5), we previously 
demonstrated that IGF-I can induce hepatocyte DNA synthesis and cell 
proliferation in primary cultures, mediated by signal transducers such as 
receptor tyrosine kinase, PI(3)K, MAP kinase, and p70 S6 kinase (Kimura 
and Ogihara, 1998). In addition, when combined with IGF-I treatment (10 
nM), L-ascorbic acid (10-7 M) and L-ascorbic acid 2-glucoside (10-7 M) 
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stimulated hepatocyte DNA synthesis and proliferation in an additive 
manner (data not shown). 
The IGFs are a family of polypeptide hormones that have close structural 
and functional homologies with insulin (Ullrich et al., 1986). IGF peptides 
act as autocrine growth factors and are implicated in the regulation of fetal 
growth and development. The effects of IGF are triggered when these 
ligands bind to their specific IGF receptor. IGF receptors are members of 
the tyrosine kinase receptor family (e.g., EGF, HGF, and platelet-derived 
growth factor receptors). IGF and insulin receptors are highly homologous, 
heterotetrameric molecules composed of two extracellular -subunits 
(which contain the binding site) and two transmembrane -subunits (which 
have tyrosine kinase activity, activated in response to ligand binding). 
Thus, binding of an IGF to its receptor triggers a cascade of events that 
includes receptor autophosphorylation, phosphorylation of intracellular 
substrates, and activation of signaling pathways involved in growth 
regulation and metabolic processes (Czech, 1989; Davis, 1993; Humbel, 
1990; Lund et al., 1986; Myers et al., 1993; Parrizas et al., 1997). IGF-I 
receptor-mediated signal transduction pathways in normal and cancer cells 
have been studied in detail (Blume-Jensen and Hunter, 2001; Kurmasheva 
and Houghton, 2006; Melmed et al., 1996; Zha et al., 2010). 
To further confirm that L-ascorbic acid and L-ascorbic acid 2-glucoside 
induce hepatocyte DNA synthesis and cell proliferation through the IGF-I 
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receptor-mediated signal transduction pathway, we investigated whether 
or not these agents actually stimulate IGF-I receptor tyrosine kinase and 
MAP kinase activities. Western blot analysis showed that L-ascorbic acid 
and L-ascorbic acid 2-glucoside can stimulate both hepatic IGF-I receptor 
tyrosine kinase and MAP kinase activities (Fig. 6). These effects were 
blocked by specific inhibitors of receptor tyrosine kinase, which suggests 
that both L-ascorbic acid and L-ascorbic acid 2-glucoside act as IGF-I 
receptor agonists to induce hepatocyte mitogenesis (Fig. 6A). In addition, 
AG1478, AG538, and LY294002 inhibited L-ascorbic acid- and L-ascorbic 
acid 2-glucoside-induced increases in the phosphorylation of p42 MAP 
kinase (Fig. 6B), whereas rapamycin had no effect (Fig. 6B).  
The primary event in the action of IGF-I on cultured hepatocytes is the 
binding to specific receptors on the cell surface. To confirm involvement of 
IGF-I receptors in the induction of hepatocyte DNA synthesis and 
proliferation by L-ascorbic acid and L-ascorbic acid 2-glucoside, we 
performed [125I]-IGF-I binding test. As shown in Fig. 7A, we demonstrated 
the specific bindings of [125I]-IGF-I to IGF-I receptor on primary cultured 
hepatocytes. Then, specificity of L-ascorbic acid and its analogues on the 
IGF-I receptors was demonstrated by competitive [125I]-IGF-I binding study. 
Fig.7B showed that the IC50 value of L-ascorbic acid 2-glucoside was about 
5-fold potent than L-ascorbic acid in displacing [125I]-IGF-I. Therefore, there 
is a close relation between specific binding of L-ascorbic acid and L-ascorbic 
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acid 2-glucoside to IGF-I receptor (Fig. 7A, B) and L-ascorbic acid- and 
L-ascorbic acid 2-glucoside-induced DNA synthesis and cell proliferation in 
primary cultures of adult rat hepatocytes (Fig. 2A, B)  Taken together, a 
novel signal transduction pathway can rationally account for the 
hepatocyte DNA synthesis and cell proliferation induced by L-ascorbic acid 
and L-ascorbic acid 2-glucoside (Fig. 8). 
In conclusion, the present results demonstrate for the first time that 
L-ascorbic acid and its stable analogue, L-ascorbic acid 2-glucoside, can 
induce hepatocyte DNA synthesis and cell proliferation in primary cultures 
of adult rat hepatocytes. The effects of L-ascorbic acid and L-ascorbic acid 
2-glucoside are apparently mediated by their interaction with IGF-I 
receptor and subsequent activation of IGF-I receptor tyrosine kinase. Other 
possible interactions involve downstream PI(3)K, MAP kinase, and p70 
S6K to induce hepatocyte mitogenesis. Although the physiological 
significance of L-ascorbic acid cannot be properly gauged from this in vitro 
study alone, the novel signaling mechanisms induced by L-ascorbic acid 
and L-ascorbic acid 2-glucoside may provide strategies for hepatocyte 
proliferation therapy during liver regeneration in vivo. In addition, 
L-ascorbic acid and L-ascorbic acid 2-glucoside may be used as safe agonists 
to cure diseases such as growth failure, muscular dystrophy, and type II 
diabetes.  
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6. Legends 
 
Fig. 1 Time course for the stimulation of hepatocyte DNA synthesis and cell 
proliferation induced by L-ascorbic acid and its analogues. Hepatocytes at a 
cell density of 3.3  104 cells/cm2 were plated and cultured in minimum 
essential medium containing 5% newborn calf serum and 0.1 nM 
dexamethasone for 3 h. After the 3-h attachment period (time zero), the 
medium was rapidly replaced with serum-free minimum essential medium 
and the hepatocytes were cultured with L-ascorbic acid (3  10-6 M), 
L-ascorbic acid 2-glucoside (10-6 M), dehydroascorbic acid (3  10-6 M), or 
isoascorbic acid (3  10-6 M) for an additional period of time. Hepatocyte 
DNA synthesis (A) and cell proliferation (B) were determined as described 
in Section 2. Data are expressed as mean  S.E.M. of three separate 
experiments. *P < 0.05, **P < 0.01 compared with the respective control. 
 
Fig. 2 Dose-dependent effects of L-ascorbic acid and its analogues on 
hepatocyte DNA synthesis and cell proliferation. Hepatocytes at a cell 
density of 3.3  104 cells/cm2 were plated and cultured for 3 h as described 
in the legend to Fig. 1. After the 3-h attachment period (time zero), the 
medium was rapidly replaced with serum-free minimum essential medium 
and the hepatocytes were cultured with various concentrations of 
L-ascorbic acid or its analogues for an additional 4 h. Hepatocyte DNA 
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synthesis (A) and cell proliferation (B) were determined as described in 
Section 2. Data are expressed as mean  S.E.M. of three separate 
experiments. *P < 0.05, **P < 0.01 compared with the respective control. 
 
Fig. 3 Effects of specific inhibitors of growth-related signal transducers on 
hepatocyte DNA synthesis and cell proliferation induced by L-ascorbic acid 
or L-ascorbic acid 2-glucoside. Hepatocytes at a cell density of 3.3  104 
cells/cm2 were plated and cultured for 3 h as described in the legend to Fig. 
1. After the 3-h attachment period (time zero), the medium was rapidly 
replaced with serum-free minimum essential medium and the hepatocytes 
were cultured with L-ascorbic acid or L-ascorbic acid 2-glucoside in the 
presence of specific inhibitors of growth-related signal transducers for an 
additional 4 h. Concentrations were as follows: AG1478 (3  10-6 M), 
LY294002 (10-7 M), PD98059 (10-6 M), and rapamycin (10 ng/ml). 
Hepatocyte DNA synthesis (A) and cell proliferation (B) were determined 
as described in Section 2. Data are expressed as mean  S.E.M. of three 
separate experiments. *P < 0.05, **P < 0.01 compared with the respective 
control. 
 
Fig. 4 Effect of anti-growth factor receptor monoclonal antibodies on 
L-ascorbic acid- and L-ascorbic acid 2-glucoside-induced hepatocyte DNA 
synthesis and cell proliferation. Hepatocytes at a cell density of 3.3  104 
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cells/cm2 were plated and cultured for 3 h as described in the legend to Fig. 
1. After the 3-h attachment period (time zero), the medium was rapidly 
replaced with serum-free minimum essential medium and the hepatocytes 
were cultured with submaximal concentrations of monoclonal antibodies 
against hepatocyte growth factor (HGF) receptor (100 ng/ml), epidermal 
growth factor (EGF) receptor (100 ng/ml), insulin receptor (100 ng/ml), 
insulin-like growth factor (IGF)-I receptor (100 ng/ml), IGF-II receptor (100 
ng/ml) or tumor necrosis factor (TNF)- receptor-1(100 ng/ml) in the 
presence of L-ascorbic acid (3  10-6 M) or L-ascorbic acid 2-glucoside (10-6 
M) for an additional 4 h. Hepatocyte DNA synthesis (A) and cell 
proliferation (B) were determined as described in Section 2. Data are 
expressed as mean  S.E.M. of three separate experiments. **P < 0.01 
compared with the respective control. 
 
Fig. 5 Dose-dependent effects of monoclonal antibodies against IGF-I 
receptor, transforming growth factor (TGF)-, and IGF-I on hepatocyte 
DNA synthesis and cell proliferation induced by L-ascorbic acid or 
L-ascorbic acid 2-glucoside. Hepatocytes at a cell density of 3.3  104 
cells/cm2 were plated and cultured for 3 h as described in the legend to Fig. 
1. After the 3-h attachment period (time zero), the medium was rapidly 
replaced with serum-free minimum essential medium and the hepatocytes 
were cultured with various concentrations of monoclonal antibodies against 
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IGF-I receptor, TGF-, or IGF-I in the presence of L-ascorbic acid (3  10-6 
M) or L-ascorbic acid 2-glucoside (10-6 M) for an additional 4 h. Hepatocyte 
DNA synthesis (A) and cell proliferation (B) were determined as described 
in Section 2. Data are expressed as mean  S.E.M. of three separate 
experiments. *P < 0.05, **P < 0.01 compared with the respective control. 
 
Fig. 6 Effects of L-ascorbic acid- and L-ascorbic acid 2-glucoside on receptor 
tyrosine kinase and mitogen-activated protein (MAP) kinase activity in 
primary cultured hepatocytes. Hepatocytes at a cell density of 3.3  104 
cells/cm2 were plated and cultured for 3 h as described in the legend to Fig. 
1. The phosphorylation of IGF-I receptor and p42 MAP kinase by L-ascorbic 
acid and L-ascorbic acid 2-glucoside was described in the Materials and 
Methods section. In brief, hepatocytes were seeded and cultured as 
described in the legend to Fig. 1. After changing the medium, the cells were 
treated with L-ascorbic acid or L-ascorbic acid 2-glucoside in the presence 
or absence of AG1478 (3  10-6 M), LY294002 (10-7 M), PD98059 (10-6 M), 
rapamycin (10 ng/ml) or AG538 (10-7 M) for 3 and 5 min, then lysed. Cell 
lysates were centrifuged and the supernatant proteins were resolved using 
sodium dodecyl sulfate (SDS)-PAGE (30 g/lane). Proteins were transferred 
to a polyvinylidene difluoride (PVDF) membrane and immunoblotted with 
a phospho-IGF-I receptor or antibody, or with phospho-MAP kinase 
antibody, and the blots was probed using horseradish peroxidase 
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(HRP)-conjugated secondary antibody. A typical Western blot image is 
shown at the top of the figure. Results are expressed as a percentage of the 
respective control value (mean  S.E.M. of three experiments). 
 
Fig. 7 Specific binding of [125I]-IGF-I to IGF-I receptor on primary cultures 
of hepatocytes as a function of [125I]-IGF-I concentration (A). Specific 
binding was determined as described under Materials and Methods section. 
Values are means for two experiments. Inset; Scatchard plot of [125I]-IGF-I 
binding to IGF-I receptor on the primary cultured hepatocytes. 
Displacement of [125I]-IGF-I on IGF-I receptors of primary cultured 
hepatocytes by L-ascorbic acid and its analogues (B). The primary cultures 
of hepatocytes were incubated for 2h at 20C with 50 pM [125I]-IGF-I and 
various concentrations of L-ascorbic acid and its analogues as described 
under Materials and Methods section. Values are means for two 
experiments. The IC50 is defined as the concentration of competing ligand 
which inhibits 50% of the specific binding of [125I]-IGF-I. The IC50 values for 
IGF-I, L-ascorbic acid, and L-ascorbic acid 2-glucoside were 4.3x10-10 M, 
1.8x10-7 M, and 5.4x10-8 M, respectively.  
 
Fig. 8 A strategy to prove L-ascorbic acid is an agonist of IGF-I receptor in 
primary cultures of adult rat hepatocytes. 
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